No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylenetetrahydrofolate-reductase gene

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 2, 1999, Pages 101-105

  Rintelen, C ^c   Mannhalter, C ^c   Lechner, K ^c   Eichinger, S ^c   Kyrle, P A ^c   Papagiannopoulos, M ^c   Schneider, B ^a   Pabinger, Ingrid ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NONE

Author keywords

Factor V Leiden mutation; MTHFR mutation; Thrombophilia; Venous thromboembolism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5;

ADULT; AGED; CONTROLLED STUDY; FAMILY STUDY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0032969605     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199903000-00007     Document Type: Review

References (22)

1. 1. Falcon CR, Marco C, Panzari D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arteriosder Thromb 1994; 14: 1080-1083.
2. 2. Fermo I, Vigano S, D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747-753.
3. 3. Den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-885.
4. 4. Den Heijer M, Koster T, Blom H, Bos GMJ, Briët E, Reitsma PH, et al. Hyperhomocysteinaemia as a risk factor for deep vein thrombosis. N Engl J Med 1996; 334: 759-762.
5. 5. Kang SS, Wong PWK. Genetic and nongenetic factors for moderate hyperhomocysteinemia. Atherosclerosis 1996; 119: 135.
6. 6. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995; 10: 111-113.
7. 7. Kluijtmans LAJ, von den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia. A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
8. 8. Trillot N, Preudhomme C, Alhenc-Gelas M, Gaveriaux V, Bauters A, Gandrille S, et al. Thermolabile methylene tetra hydrofolate reductase (MTHFR) does not modify the risk for venous thromboembolism in subjects with heterozygous factor V Leiden. Blood 1996; 88 (suppl 1): 284a.
9. 9. Kluijtmans LAJ, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 254-258.
10. 10. Legnani C, Palareti G, Sassi S, Grauso F, Bargossi A, Bernardi F, et al. Hyperhomocyst(e)inaemia and a common methylene-tetrahydrofolate reductase mutation (Ala223 Val MTHFR) are not associated with a history of thrombosis with inherited thrombophilia. Thromb Haemost 1997; (suppl): 568.
11. 506). Arterioscler Thromh Vasc Biol 1997; 17: 1662-1666.
12. 506). Thromb Haemost 1997; (suppl): 570.
13. 13. Rintelen C, Pabinger P, Knöbl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996, 75: 229-232.
14. 14. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma thrombin levels and an increase in venous thrombosis. Blood 1994; 10: 3698-3703.
15. 15. Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-1035.
16. 16. Koeleman BPC, van Rumpf D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74: 580-583.
17. 17. Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Griffin JH, Aiach M, and the French Network on the behalf of INSERM. Incidence of activated protein C resistance caused by ARG 506 GLN mutation in 113 unrelated symptomatic protein C deficient patients. Blood 1995; 86: 219-224.
18. 18. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
19. 19. Mustafa S, Mannhalter C, Rintelen C, Kyrle PA, Knoebl P, Lechner K, et al. Clinical feature in thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coag Fibrinol 1998; 9: 85-89.
20. 20. Selhub J, D'Angelo A. Hyperhomocysteinaemia and thrombosis: acquired conditions. Thromb Haemost 1997; 78: 527-531.
21. 21. Austin H, Hooper CW, Dilley A, Drews C, Renshaw M, Ellinsen D, et al. The prevalence of two genetic traits to venous thrombosis in whites and African-Americans. Thromb Res 1997; 86: 409-415.
22. 22. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, et al. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med 1996; 334: 763-768.